EN
SINOVAC actively discusses COVID-19 Vaccine application and the industry development with other countries
The Egyptian delegation led by H.E. Ambassador to China Dr. Mohamed Elbadri visited the production base of Sinovac Life Sciences in Daxing, Beijing on 21 October 2021, accompanied by Chairman Weidong Yin, and Sales General Manager Helen Yang of Sinovac Group, and Deputy General Manager Weining Meng of Sinovac Life Sciences.
During the visit, H.E. Ambassador and Mr. Yin had a teleconference with the Minister of Health and Population of Egypt Prof. Hala Zayed on the supply and localization of SINOVAC's COVID-19 Vaccine, the procurement of other vaccine products, and also the cooperation of technology license. The two parties initially reached a cooperative intention on the above discussion.
On October 21, 2021, Sales General Manager Helen Yang of Sinovac Group welcomed The Philippines delegation led by Jose Santiago L. Sta. Romana, the Philippine Ambassador to China, and together with Venince Allen Carillo, the Third Secretary, and Data Dada, the Attache.
H.E. Ambassador Romana signed the delivery certification of the second batch of CHINA AID 1 million COVID-19 vaccines to the Philippines and went to the cold storage to personally turn on the temperature recorder.
Embassy of the Republic of Indonesia in Beijing invited Sales General Manager Helen Yang of Sinovac Group to join the Indonesia-China Business Forum 2021 on the theme "New Road to Business Acceleration in Digitalization, Health and Green Economy in Indonesia" on Tuesday, 19 October 2021.
The event is organized with the Directorate General of Asia Pacific and Africa, Ministry for Foreign Affairs of the Republic of Indonesia, Bank Indonesia Representative Office in Beijing, and Indonesia Chamber of Commerce in China.
Ambassador of the Republic of Indonesia to the People's Republic of China, H.E. Mr. Djauhari Oratmangun, Vice-Minister for Foreign Affairs of the Republic of Indonesia, H.E. Mr. Mahendra Siregar attendance the forum and introduced the bilateral solid relationship development between Indonesia-China and achievements made so far and future focus on health, digitalization and green economy, etc. Industries cooperation between China and Indonesia.
Helen Yang introduced Indonesia as the first country to issue EUA Certificate to China, and further Indonesia and Sinovac close cooperation on clinical, vaccine supplies to make Indonesia be the largest COVID-19 vaccines manufacturer in ASEAN (Association of Southeast Asian Nations) countries, and also illustrates the confidence in plan to help Indonesia to be the vaccines manufacture hub.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.
SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.
SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.
With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.
For more information, please see the Company's website at www.sinovac.com.